Protease Inhibitor Use in COVID-19

被引:7
|
作者
Yueqi Song
Wujian Peng
Donge Tang
Yong Dai
机构
[1] The Second Clinical Medical College of Jinan University (Shenzhen People’s Hospital),Clinical Medical Research Center
[2] The Second Affiliated Hospital of Southern University of Science and Technology (Shenzhen Third People’s Hospital),Department of Nephrology, National Clinical Research Center for Infectious Diseases
关键词
Novel coronavirus pneumonia; Diagnosis; Treatment; Lopinavir/ritonavir;
D O I
10.1007/s42399-020-00448-0
中图分类号
学科分类号
摘要
The outbreak of a large plaque, novel coronavirus pneumonia (NCP), which also named Coronavirus Disease 2019 (COVID-19) by the WHO, has detrimentally affected the livelihood and health of people in China. During the spread of COVID-19, colleagues who have been working at the frontline have had to face many new challenges in the treatment and prevention of NCP. Therefore, we have provided suggestions for the diagnosis, treatment, and prevention of the novel coronavirus pneumonia in the current epidemic situation based on the latest reports and the experience of doctors treating COVID-19 in our hospital. We recommend lopinavir/ritonavir as the effective drugs for antiviral treatment according to our experience in administering lopinavir/ritonavir to COVID-19 patients and the successful cases of these drugs in treating MERS and SARS, but need more clinical data to prove their efficacy in treating COVID-19.
引用
收藏
页码:1436 / 1443
页数:7
相关论文
共 50 条
  • [1] Use of protease inhibitors for the prevention of COVID-19
    Sagawa, Tomoya
    Inoue, Ken-ichiro
    Takano, Hirohisa
    PREVENTIVE MEDICINE, 2020, 141
  • [2] Phenylethanoid glycosides as a possible COVID-19 protease inhibitor: a virtual screening approach
    Bernardi, Mario
    Ghaani, Mohammad Reza
    Bayazeid, Omer
    JOURNAL OF MOLECULAR MODELING, 2021, 27 (11)
  • [3] The protease inhibitor lopinavir, boosted with ritonavir, as treatment for COVID-19: a rapid review
    Dorward, Jienchi
    Gbinigie, Oghenekome
    Cai, Ting
    Roberts, Nia W.
    Garrett, Nigel
    Hayward, Gail
    Butler, Christopher C.
    ANTIVIRAL THERAPY, 2020, 25 (07) : 365 - 376
  • [4] Phenylethanoid glycosides as a possible COVID-19 protease inhibitor: a virtual screening approach
    Mario Bernardi
    Mohammad Reza Ghaani
    Omer Bayazeid
    Journal of Molecular Modeling, 2021, 27
  • [5] Repurposing metocurine as main protease inhibitor to develop novel antiviral therapy for COVID-19
    Rashi Jain
    Somdutt Mujwar
    Structural Chemistry, 2020, 31 : 2487 - 2499
  • [6] Hydroxychloroquine as Potent Inhibitor of COVID-19 Main Protease: Grid Based Docking Approach
    Malik, Jitender Kumar
    Soni, Himesh
    Sharma, Sarvesh
    Sarankar, Satish
    EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, 2020, 4 (03): : 219 - 226
  • [7] A novel robust inhibitor of papain-like protease (PLpro) as a COVID-19 drug
    Asl, Saeed Soleimani
    Roozbahani, Mohammad Hossein
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2024, 42 (13): : 6863 - 6870
  • [8] Repurposing metocurine as main protease inhibitor to develop novel antiviral therapy for COVID-19
    Jain, Rashi
    Mujwar, Somdutt
    STRUCTURAL CHEMISTRY, 2020, 31 (06) : 2487 - 2499
  • [9] Use of SGLT-2 inhibitor in COVID-19: A cautionary tale
    Yousaf, Zohaib
    Munir, Waqar
    Hammamy, Riyadh Ali Mohammed
    MEDCOMM, 2021, 2 (01): : 114 - 116
  • [10] Structural dynamics of COVID-19 main protease
    Shekaari, Ashkan
    Jafari, Mahmoud
    JOURNAL OF MOLECULAR STRUCTURE, 2021, 1223